Advances in radiotherapy technology for prostate cancer: What every GP should know

被引：0
作者：
Gorayski, Peter [1 ,2 ]
Pinkham, Mark B. [2 ,3 ]
Lehman, Margot [2 ,3 ]
机构：
[1] Radiat Oncol Queensland, Toowoomba, Qld, Australia
[2] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
来源：
AUSTRALIAN FAMILY PHYSICIAN | 2015年 / 44卷 / 09期
关键词：
BEAM RADIATION-THERAPY; RADICAL PROSTATECTOMY; CARCINOMA; IMPACT;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Background One in five Australian men are diagnosed with prostate cancer. External beam radiation therapy (EBRT) is an effective treatment for men suitable for definitive therapy. Objectives This article outlines the processes involved in EBRT for prostate cancer, with particular emphasis on recent technological advances that have had a positive impact on patient outcomes. The patient's experience is explained and comparisons are made with surgery. Discussion Patients diagnosed with localised prostate cancer may have multiple treatment options. General practitioners have an important role in helping patients navigate their way through the information needed to make this decision. Radiotherapy technologies, including image guidance, intensity-modulated radiation therapy and stereotactic (ablative) radiation therapy are discussed in this article.
引用
收藏
页码：663 / 667
页数：5
相关论文
共 20 条
  • [1] [Anonymous], NAT REV UROL
  • [2] [Anonymous], 2012, AUSTR I HLTH WELF CA
  • [3] Australian Institute of Health and Welfare, 2014, ACIM AUSTR CANC INC
  • [4] The getug 70 GY vs. 80 GY randomized trial for localized prostate cancer:: Feasibility and acute toxicity
    Beckendorf, V
    Guérif, S
    Le Prisé, E
    Cosset, JM
    Lefloch, O
    Chauvet, B
    Salem, N
    Chapet, O
    Bourdin, S
    Bachaud, JM
    Maingon, P
    Lagrange, JL
    Malissard, L
    Simon, JM
    Pommier, P
    Hay, MH
    Dubray, B
    Luporsi, E
    Bey, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04): : 1056 - 1065
  • [5] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [6] Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Fondurulia, J
    Chen, MH
    Kaplan, I
    Beard, CJ
    Tomaszewski, JE
    Renshaw, AA
    Wein, A
    Coleman, CN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 168 - 172
  • [7] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
    Dearnaley, David
    Syndikus, Isabel
    Sumo, Georges
    Bidmead, Margaret
    Bloomfield, David
    Clark, Catharine
    Gao, Annie
    Hassan, Shama
    Horwich, Alan
    Huddart, Robert
    Khoo, Vincent
    Kirkbride, Peter
    Mayles, Helen
    Mayles, Philip
    Naismith, Olivia
    Parker, Chris
    Patterson, Helen
    Russell, Martin
    Scrase, Christopher
    South, Chris
    Staffurth, John
    Hall, Emma
    [J]. LANCET ONCOLOGY, 2012, 13 (01) : 43 - 54
  • [8] Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
    Denham, JW
    Steigler, A
    Lamb, DS
    Joseph, D
    Mameghan, H
    Turner, S
    Matthews, J
    Franklin, I
    Atkinson, C
    North, J
    Poulsen, M
    Christie, D
    Spry, NA
    Tai, KH
    Wynne, C
    Duchesne, G
    Kovacev, O
    D'Este, C
    [J]. LANCET ONCOLOGY, 2005, 6 (11) : 841 - 850
  • [9] Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group
    Grimm, Peter
    Billiet, Ignace
    Bostwick, David
    Dicker, Adam P.
    Frank, Steven
    Immerzeel, Jos
    Keyes, Mira
    Kupelian, Patrick
    Lee, W. Robert
    Machtens, Stefan
    Mayadev, Jyoti
    Moran, Brian J.
    Merrick, Gregory
    Millar, Jeremy
    Roach, Mack
    Stock, Richard
    Shinohara, Katsuto
    Scholz, Mark
    Weber, Ed
    Zietman, Anthony
    Zelefsky, Michael
    Wong, Jason
    Wentworth, Stacy
    Vera, Robyn
    Langley, Stephen
    [J]. BJU INTERNATIONAL, 2012, 109 : 22 - 29
  • [10] Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population
    Hanlon, AL
    Bruner, DW
    Peter, R
    Hanks, GE
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (01): : 51 - 59
12